Neoadjuvant hormone therapy before salvage radiotherapy for an increasing post-radical prostatectomy serum prostate specific antigen level

Journal of Urology

Volumn 170, Issue 2 I, 2003, Pages 447-450

  Tiguert, Rabi ^a   Rigaud, Jérôme ^a   Lacombe, Louis ^a   Laverdière, Jacques ^a   Fradet, Yves ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b Université Laval   (Canada)

Author keywords

Androgens; Prostate specific antigen; Prostatectomy; Radiotherapy

Indexed keywords

ANDROGEN; GONADORELIN DERIVATIVE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BEAM THERAPY; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RADIATION DOSE; RETROSPECTIVE STUDY;

EID: 0037477389     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000075351.51838.b3     Document Type: Article

References (20)

1. Jhaveri, F. M. and Klein, E. A.: How to explore the patient with a rising PSA after radical prostatectomy: defining local versus systemic failure. Semin Urol Oncol, 17: 130, 1999
2. Tiguert, R., Forman, J. D., Hussain, M. and Wood, D. P., Jr.: Radiation therapy for a rising PSA level after radical prostatectomy. Sem Urol Oncol, 17: 141, 1999
3. Shekarriz, B., Upadhyay, J., Wood, D. P., Jr., Hinman, J., Raasch, J., Cummings, G. D. et al: Vesicourethral anastomosis biopsy after radical prostatectomy: predictive value of prostate-specific antigen and pathologic stage. Urology, 54: 1044, 1999
4. Koppie, T. M., Grossfeld, G. D., Nudell, D. M., Weinberg, V. K. and Carroll, P. R.: Is anastomotic biopsy necessary before radiotherapy after radical prostatectomy? J Urol, 166: 111, 2001
5. Saleem, M. D., Sanders, H., Abu El Naser, M. and El-Galley, R.: Factors predicting cancer detection in biopsy of the prostatic fossa after radical prostatectomy. Urology, 51: 283, 1998
6. Rorvik, J. and Haukaas, S.: Magnetic resonance imaging of the prostate. Curr Opin Urol, 11: 181, 2001
7. Pontes, J. E., Yousif, R., Tiguert, R., Bianco, F. J., Gheiler, E. L. and Wood, D. P.: Value of computed tomography in detecting recurrence following radical prostatectomy. J Urol, suppl., 163: 326, abstract 1446, 2000
8. Sodee, D. B., Malguria, N., Faulhaber, P., Resnick, M. I., Albert, J. and Bakale, G.: Multicenter ProstaScint imaging findings in 2154 patients with prostate cancer. The ProstaScint Imaging Centers. Urology, 56: 988, 2000
9. Grossfeld, G. D., Li, Y.-P., Lubeck, D. P., Broering, J. M., Mehta, S. S. and Carroll, P. R.: Predictors of secondary cancer treatment in patients receiving local therapy for prostate cancer: data from cancer of the prostate strategic urologic research endeavor. J Urol, 168: 530, 2002
10. Pisansky, T. M., Kozelsky, T. F., Myers, R. P., Hillman, D. W., Blute, M. L., Buskirk, S. J. et al: Radiotherapy for isolated serum prostate specific antigen elevation after prostatectomy for prostate cancer. J Urol, 163: 845, 2000
11. Anscher, M. S., Clough, R. and Dodge, R.: Radiotherapy for a rising prostate-specific antigen after radical prostatectomy: the first 10 years. Int J Radiat Oncol Biol Phys, 48: 369, 2000
12. Cadeddu, J. A., Partin, A. W., DeWeese, T. L. and Walsh, P. C.: Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy. J Urol, 159: 173, 1998
13. Eulau, S. M., Tate, D. J., Stamey, T. A., Bagshaw, M. A. and Hancock, S. L.: Effect of combined transient androgen deprivation and irradiation following radical prostatectomy for prostatic cancer. Int J Radiat Oncol Biol Phys, 41: 735, 1998
14. Zelefsky, M. J., Lyass, O., Fuks, Z., Wolfe, T., Burman, C., Ling, C. C. et al: Predictors of improved outcome for patients with localized prostate cancer treated with neoadjuvant androgen ablation therapy and three-dimensional conformal radiotherapy. J Clin Oncol, 16: 3380, 1998
15. Sobin, L. H. and Wittekind, Ch.: International Union Against Cancer (UICC). TNM Classification of Malignant Tumours, 5th ed. New York: John Wiley & Sons, Inc., 1997
16. Gleason, D. F.: Atypical hyperplasia, and well differentiated adenocarcinoma of the prostate. Am J Surg Pathol, suppl., 9: 53, 1985
17. Laverdiere, J., Gomez, J. L., Cusan, L., Suburu, E. R., Diamond, P., Lemay, M. et al: Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys, 37: 247, 1997
18. Cox, J. D., Stetz, J. and Pajak, T. F.: Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys, 31: 1341, 1995
19. Soh, S., Kattan, M. W., Berkman, S., Wheeler, T. M. and Scardino, P. T.: Has there been a recent shift in the pathological features and prognosis of patients treated with radical prostatectomy? J Urol, 157: 2212, 1997
20. Cox, J. D., Gallagher, M. J., Hammond, E. H., Kaplan, R. S. and Schellhammer, P. F.: Consensus statement on radiation therapy of prostate cancer: guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate specific antigen levels after radical prostatectomy. American Society for Therapeutic Radiology and Oncology Consensus Panel. J Clin Oncol, 17: 1155, 1999